Efficacy and Safety of Re-Challenging 160 Mg Furmonertinib for Advanced NSCLC after Resistance to Third-Generation EGFR-TKIs Targeted Agents: A Real-World Study.
Lung Cancer（2023）
关键词
NSCLC,EGFR-TKI,Furmonertinib,Re-challenging
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要